Geriatric assessment of multiple myeloma

Multiple myeloma is a haemopathy of the elderly. The study of frailty is of great interest in the management of these patients. The aim of our study was to determine the epidemiological diagnostic and prognostic characteristics of elderly subjects with multiple myeloma and to assess the impact of frailty testing on overall survival treatment-related toxicity and event-free follow-up.The median age was 73 years (range 65-89 years). Bone pain was the most frequent finding in 40% of cases. Renal involvement was noted in 42% of patients. Half the patients were treated according to the MPT (melphalan-prednisone-thalidomide) protocol. The most frequently reported toxicity was neurological. The most serious toxicities were infectious. A study of frailty would be of great interest in orienting therapeutic management in this age group. An initial score that takes into account frailty tests and hematological prognostic factors would have a better predictive value in terms of overall survival and event-free survival.